Lilly Advances IL23 Gastroenterology Ambitions With Mirikizumab In Crohn&39;s Disease

The company reported positive Phase II results and will move its potential fourthtomarket IL23 inhibitor into Phase III in Crohn&39;s...&160;&160;&160;